SCYNEXIS, Inc. SCYX
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $33.00 (+665.7% upside)
Key Stats
- Today's Range
- $4.30 – $4.59
- 50-Day Range
- $3.53 – $6.09
- 52-Week Range
- $3.53 – $10.48
- Volume
- 20K shs
- Average Volume
- 74K shs
- Market Cap
- $44.38 million
- P/E Ratio
- 14.86
- Dividend Yield
- —
Valuation
- P/E Ratio
- 14.86
- Price / Book
- 0.66
- Price / Sales
- 2.31
Short Interest
- Short Interest
- 13.22%
- Days to Cover
- 10.66
Financials (TTM)
- Revenue
- $19.21 million
- Net Income
- $-10,235,000
- Net Margin
- -53.27%
- Return on Equity
- -15.29%
- Debt-to-Equity
- —
About SCYNEXIS, Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Related Stocks
Compare head-to-head: SCYX vs LLY·SCYX vs JNJ·SCYX vs ABBV·SCYX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.